Elicio Therapeutics (ELTX) Research & Development (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Research & Development for 7 consecutive years, with $6.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 2.78% year-over-year to $6.8 million; the trailing twelve-month figure through Jun 2026 stood at $23.7 million (down 27.56% YoY), and the FY2025 full-year result was $24.9 million, down 26.01% from the prior year.
• Research & Development advanced to $6.8 million in Q2 2026 per ELTX's latest filing, from $6.8 million in the prior quarter.
• Across five years, Research & Development topped out at $11.7 million in Q1 2022 and bottomed at $4.3 million in Q4 2022.
• Historically, Research & Development has averaged $6.8 million across 5 years, with a median of $6.8 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Research & Development plunged 65.43% in 2022, then jumped 73.93% in 2024.
• Over 5 years, Research & Development stood at $4.3 million in 2022, then surged by 43.52% to $6.2 million in 2023, then surged by 73.93% to $10.7 million in 2024, then sank by 52.56% to $5.1 million in 2025, then surged by 34.07% to $6.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $6.8 million, $6.8 million, and $5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.